Enzastaurin

Bibliography

• Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998;332:281-92
   PubMed Web of Science ®Google Scholar
• Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007;16:1693-707.
   PubMed Web of Science ®Google Scholar
• Gokmen-Polar Y, Murray NR, Velasco MA, et al. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 2001;61:1375-81.
   PubMed Web of Science ®Google Scholar
• Engers R, Mrzyk S, Springer E, et al. Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression. Br J Cancer 2000;82:1063-9.
   PubMed Web of Science ®Google Scholar
• Tsai JH, Hsieh YS, Kuo SJ, et al. Alteration in the expression of protein kinase C isoforms in human hepatocellular carcinoma. Cancer Lett 2000;161:171-5
   PubMed Web of Science ®Google Scholar
• Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 2003;63:780-6
   PubMed Web of Science ®Google Scholar
• Li H, Weinstein IB. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res 2006;66:11399-408
   PubMed Web of Science ®Google Scholar
• Svensson K, Zeidman R, Troller U, et al. Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation. Cell Growth Differ 2000;11:641-8
   PubMedGoogle Scholar
• Koren R, Ben Meir D, Langzam L, et al. Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol Rep 2004;11:321-6
   PubMed Web of Science ®Google Scholar
• Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002;99:721-6
   PubMed Web of Science ®Google Scholar
• Xia P, Aiello LP, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-26
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9
   PubMed Web of Science ®Google Scholar
• Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the I-kappa B kinase alpha. J Exp Med 2002;195:1647-52
   PubMed Web of Science ®Google Scholar
• Shinohara H, Yasuda T, Aiba Y, et al. PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 2005;202:1423-31
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377-84
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74
   PubMed Web of Science ®Google Scholar
• Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007;109:4964-72
   PubMed Web of Science ®Google Scholar
• Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007;109:1669-77
   PubMed Web of Science ®Google Scholar
• Abrams ST, Lakum T, Lin K, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C beta II. Blood 2007;109:1193-201
   PubMed Web of Science ®Google Scholar
• Decouvelaere AV, Morschhauser F, Buob D, et al. Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology 2007;50:561-6
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641-7
   PubMed Web of Science ®Google Scholar
• Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKC beta. Bioorg Med Chem Lett 2003;13:1857-9
   PubMed Web of Science ®Google Scholar
• Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol 2007;19:590-5
   PubMed Web of Science ®Google Scholar
• Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9
   PubMed Web of Science ®Google Scholar
• Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004;53:133-40
   PubMed Web of Science ®Google Scholar
• Teicher BA, Alvarez E, Menon K, et al. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother Pharmacol 2002;49:69-77
   PubMed Web of Science ®Google Scholar
• Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71
   PubMed Web of Science ®Google Scholar
• Balendran A, Hare GR, Kieloch A, et al. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 2000;484:217-23
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Nishimoto H, Kitaura J, et al. Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J Biol Chem 2004;279:47720-5
   PubMed Web of Science ®Google Scholar
• Camidge DR, Gail Eckhardt S, Gore L, et al. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 2008;19:77-84
   PubMed Web of Science ®Google Scholar
• Beerepoot LV, Rademaker-Lakhai JM, Witteveen EO, et al. Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer. J Clin Oncol 2006;24:2046a
   Web of Science ®Google Scholar
• Hanauske A, Weigang KK, Yilmaz E, et al. Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer. J Clin Oncol 2006;24:2047a
   Google Scholar
• Bepler G, OY, Burris H, et al. A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2007;24(Suppl):2047
   Google Scholar
• Fine H, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 2005;23:1504a
   Google Scholar
• Butowski NA, Lamborn K, Chang S, et al. Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma. J Clin Oncol 2007;25:12511
   Google Scholar
• Spalding AC, Watson R, Davis ME, et al. Inhibition of protein kinase C beta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. Clin Cancer Res 2007;13:6827-33
   PubMed Web of Science ®Google Scholar
• Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 2007;61:153-61
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Zwolak P, Jasinski P, et al. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest New Drugs 2008;26:13-24
   PubMed Web of Science ®Google Scholar
• Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90:3167-72
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6
   PubMed Web of Science ®Google Scholar
• Clinical Trials website. Available from: http://www.clinicaltrials.gov [Last accessed 11 April 2008]
   Google Scholar
• Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247-53
   PubMed Web of Science ®Google Scholar
• Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35
   PubMed Web of Science ®Google Scholar
• Dring AM, Davies FE, Fenton JA, et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 2004;10:5692-701
   PubMed Web of Science ®Google Scholar
• Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783-9
   PubMed Web of Science ®Google Scholar
• Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007;110:4417-26
   PubMed Web of Science ®Google Scholar